152 related articles for article (PubMed ID: 17696754)
41. Fluorinated glycosyl amino acids for mucin-like glycopeptide antigen analogues.
Wagner S; Mersch C; Hoffmann-Röder A
Chemistry; 2010 Jun; 16(24):7319-30. PubMed ID: 20461825
[TBL] [Abstract][Full Text] [Related]
42. [MUC1, a therapeutic target in oncology].
Limacher JM; Acres B
Bull Cancer; 2007 Mar; 94(3):253-7. PubMed ID: 17371767
[TBL] [Abstract][Full Text] [Related]
43. Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs.
Wang Y; Liu C; Xia Q; Wang P; Li B; Lu Z; Sun J; Wu H; Yu B; Wu J; Yu X; Kong W; Zhang H; Cong X
Oncol Rep; 2014 Mar; 31(3):1437-44. PubMed ID: 24378623
[TBL] [Abstract][Full Text] [Related]
44. MUC1 in endometriosis and ovarian cancer.
Vlad AM; Diaconu I; Gantt KR
Immunol Res; 2006; 36(1-3):229-36. PubMed ID: 17337783
[TBL] [Abstract][Full Text] [Related]
45. Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and a T-cell epitope for the induction of a highly specific humoral immune response.
Westerlind U; Hobel A; Gaidzik N; Schmitt E; Kunz H
Angew Chem Int Ed Engl; 2008; 47(39):7551-6. PubMed ID: 18704911
[No Abstract] [Full Text] [Related]
46. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
[TBL] [Abstract][Full Text] [Related]
47. Microvesicle cargo of tumor-associated MUC1 to dendritic cells allows cross-presentation and specific carbohydrate processing.
Rughetti A; Rahimi H; Belleudi F; Napoletano C; Battisti F; Zizzari IG; Antonilli M; Bellati F; Wandall HH; Benedetti Panici P; Burchell JM; Torrisi MR; Nuti M
Cancer Immunol Res; 2014 Feb; 2(2):177-86. PubMed ID: 24778281
[TBL] [Abstract][Full Text] [Related]
48. The development of synthetic antitumour vaccines from mucin glycopeptide antigens.
Gaidzik N; Westerlind U; Kunz H
Chem Soc Rev; 2013 May; 42(10):4421-42. PubMed ID: 23440054
[TBL] [Abstract][Full Text] [Related]
49. MUC1 immunotherapy.
Beatson RE; Taylor-Papadimitriou J; Burchell JM
Immunotherapy; 2010 May; 2(3):305-27. PubMed ID: 20635898
[TBL] [Abstract][Full Text] [Related]
50. Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes.
Kontani K; Taguchi O; Narita T; Izawa M; Hiraiwa N; Zenita K; Takeuchi T; Murai H; Miura S; Kannagi R
Br J Cancer; 2001 May; 84(9):1258-64. PubMed ID: 11336479
[TBL] [Abstract][Full Text] [Related]
51. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
[TBL] [Abstract][Full Text] [Related]
52. Preventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas.
Beatty PL; Finn OJ
Ann N Y Acad Sci; 2013 May; 1284():52-6. PubMed ID: 23651193
[TBL] [Abstract][Full Text] [Related]
53. Induction of MUC1-specific cellular immunity by a recombinant BCG expressing human MUC1 and secreting IL2.
He J; Shen D; O'Donnell MA; Chang HR
Int J Oncol; 2002 Jun; 20(6):1305-11. PubMed ID: 12012014
[TBL] [Abstract][Full Text] [Related]
54. The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy.
Agrawal B; Gendler SJ; Longenecker BM
Mol Med Today; 1998 Sep; 4(9):397-403. PubMed ID: 9791863
[TBL] [Abstract][Full Text] [Related]
55. Molecular evolution of specific human antibody against MUC1 mucin results in improved recognition of the antigen on tumor cells.
Persson J; Bäckström M; Johansson H; Jirström K; Hansson GC; Ohlin M
Tumour Biol; 2009; 30(4):221-31. PubMed ID: 19776674
[TBL] [Abstract][Full Text] [Related]
56. Protocol to prepare MUC1 glycopeptide vaccines and evaluate immunization effects in mice.
Wu Y; Zhou Y; Guo Y; Ling Y; Li Y; Cai H
STAR Protoc; 2024 Jun; 5(2):103047. PubMed ID: 38691463
[TBL] [Abstract][Full Text] [Related]
57. Perfluoroalkylated amphiphilic MUC1 glycopeptide antigens as tools for cancer immunotherapy.
Hoffmann-Röder A; Schoenhentz J; Wagner S; Schmitt E
Chem Commun (Camb); 2011 Jan; 47(1):382-4. PubMed ID: 20830350
[TBL] [Abstract][Full Text] [Related]
58. A novel chimeric DNA vaccine: enhancement of preventive and therapeutic efficacy of DNA vaccine by fusion of Mucin 1 to a heat shock protein 70 gene.
Choi DH; Woo JK; Choi Y; Seo HS; Kim CW
Mol Med Rep; 2011; 4(5):885-90. PubMed ID: 21725596
[TBL] [Abstract][Full Text] [Related]
59. Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.
Cai H; Sun ZY; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
Chemistry; 2013 Feb; 19(6):1962-70. PubMed ID: 23280874
[TBL] [Abstract][Full Text] [Related]
60. Synthesis of tumor-associated MUC1-glycopeptides and their multivalent presentation by functionalized gold colloids.
Tavernaro I; Hartmann S; Sommer L; Hausmann H; Rohner C; Ruehl M; Hoffmann-Roeder A; Schlecht S
Org Biomol Chem; 2015 Jan; 13(1):81-97. PubMed ID: 25212389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
